Price
No data yet.
Social Signal Score
Analyst Ratings
20 analystsRevenue
$70.38M+203.16%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- George W. LeMaitre
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 651
- Beta
- 0.49
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 7.07
Financials
Revenue
$70.38M+203.2%Net Income
$17.05M+428.0%EBITDA
$23.04M+272.2%Free Cash Flow
$13.65M+136.0%EPS (diluted)
$0.74+335.3%Shares Outstanding (diluted)
24.53M+27.4%Operating Expenses
$30.36MCash & Debt
$376.24MReturn of Capital
$5.83MDividend per Share
$0.25Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $249.60M | $57.73M | $2.55 |
| 2024 | $219.86M | $44.04M | $1.96 |
| 2023 | $193.48M | $30.11M | $1.36 |
| 2022 | $161.65M | $20.64M | $0.94 |
| 2021 | $154.42M | $26.91M | $1.27 |
| 2020 | $129.37M | $21.22M | $1.05 |
| 2019 | $117.23M | $17.93M | $0.91 |
| 2018 | $105.57M | $22.94M | $1.18 |
| 2017 | $100.87M | $17.18M | $0.91 |
| 2016 | $89.15M | $10.59M | $0.57 |
| 2015 | $78.35M | $7.76M | $0.44 |
| 2014 | $71.10M | $3.92M | $0.24 |
| 2013 | $64.55M | $3.20M | $0.21 |
| 2012 | $56.73M | $2.57M | $0.17 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from LMAT's reported EPS growth of 23.2% a year over 13 years.
- EPS in 5 years
- $7.24
- Implied price
- $231.63
- Return from $78.96
- 24.0% a year
To earn 15.0% a year on these assumptions you'd need to buy at $115.16 — today's price is already 31.4% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 22 | 27 | 32 | 37 | 42 |
|---|---|---|---|---|---|
| 13.2% | 5.7% | 10.1% | 13.9% | 17.3% | 20.3% |
| 18.2% | 10.4% | 15.0% | 19.0% | 22.5% | 25.6% |
| 23.2% | 15.1% | 19.9% | 24.0% | 27.7% | 30.9% |
| 28.2% | 19.7% | 24.7% | 29.0% | 32.9% | 36.3% |
| 33.2% | 24.4% | 29.6% | 34.1% | 38.0% | 41.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
103+6.03%Social Signal Score
Mentions (4)
- Newsseekingalpha.com·5d ago·Neutral
…A Stronger Acquisition Machine LeMaitre Vascular is rated a "Strong Buy" due to its robust M&A-driven business model, high margins, and recent valuation compression. LMAT's strategic shift to larger, higher-multiple acquisitions has improved its success rate to 80% and driven margin expansion, with gross margin rising from 65% to 72%. The company's healthy balance sheet, $376M in cash/short-term investments, and experienced management underpin its ability to pursue disciplined, accretive deals.
View source ↗ - Newsprnewswire.com·12d ago·Neutral
LeMaitre Vascular Data Breach Investigation: Edelson Lechtzin LLP Probes Class Action Claims After Customer Data Is Exposed National class action law firm offers free, confidential case evaluations to LeMaitre Vascular investors, tenants, partners, and others whose personal information may have been exposed in the reported data breach. NEWTOWN, Pa.
View source ↗ - Newsglobenewswire.com·39d ago·Neutral
LeMaitre to Participate at Upcoming Investor Conferences in September BURLINGTON, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in three upcoming investor conferences.
View source ↗ - Newsseekingalpha.com·54d ago·Neutral
LeMaitre Vascular: 31% Drawdown On $0.02 Guidance Cut LeMaitre Vascular remains a Buy after a 31% pullback, though I have trimmed my price target to $95-$100 for year-end 2027. The Q2 2026 miss was tied to currency, export blockages, and tissue shortages. Not underlying demand. Organic sales grew 10%, and margins hit record highs. Artegraft, now 21% of sales, is LMAT's largest and fastest-growing product. It is the main factor behind margin expansion and international growth prospects.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $0.69 per share
Typical surprise +1.5% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$0.74 vs $0.81miss
- Tue, May 5$0.68 vs $0.66beat
- Wed, Feb 25$0.68 vs $0.67beat
- Thu, Nov 6$0.62 vs $0.56beat
- Tue, Aug 5$0.60 vs $0.57beat
- Thu, May 1$0.48 vs $0.50miss
Estimates and results for LMAT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by LMAT officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in LMAT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.